FHIT as tumor suppressor: Mechanisms and therapeutic opportunities

Cancer Biology and Therapy

Volumn 1, Issue 3, 2002, Pages 232-236

  Pekarsky, Yuri ^a   Palamarchuk, Alexey ^a   Huebner, Kay ^a   Croce, Carlo M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID ANHYDRIDE HYDROLASE; FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR PROTEIN;

ANIMAL; CELL TRANSFORMATION; CHROMOSOME 3; CHROMOSOME ABERRATION; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT; NEOPLASM; PHYSIOLOGY; REVIEW; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASMS;

EID: 0346845249     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.73     Document Type: Review

References (42)

1. Croce CM. Role of chromosome translocations in human neoplasia. Cell 1987; 49:155-6.
2. Soloman E, Borrow J, Goddart A. Chromosome aberrations and cancer. Science 1991; 254:1153-60. (Pubitemid 21917440)
3. ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce CM. Differential expression of the translocated and of the untranslocated c-myc oncogene in Burkitt lymphoma. Science 1983; 222:390-3.
4. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228:1440-3.
5. Arakawa H, Nakamura T, Zhadanov AB, Fidanza V, Yano T, Bullrich F, et al. Identification and characterization of the ARP1 gene, a target for the human acute leukemia ALL1 gene. Proc Natl Acad Sci USA 1998; 95:4573-8.
6. Weinberg R. Tumor suppressor genes. Science 1991; 254:1138-46. (Pubitemid 21917438)
7. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-47. (Pubitemid 27148818)
8. Wigler MH, Parsons R, Druck T, Kastury K, Hadaczek P, et al. Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas. Cancer Res 1995; 55:5348-53.
9. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, Inoue H, et al. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996; 56:978-83. (Pubitemid 26065389)
10. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. Loss of heterozygosity of chromosome 3p markers in small cell lung cancer. Nature 1987; 329:451-4. (Pubitemid 17128316)
11. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, et al. Three distinct regions involved in 3p deletions in human lung cancer. Oncogene 1992; 7:445-9.
12. Huebner K, Hadaczek P, Siprashvili Z, Druck T, Croce CM. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochem Biophys Acta (Reviews on Cancer) 1997; 1332:M65-70.
13. Glover TW, Coyle-Morris JF, Li FP, Brown RS, Berger CS, Gemmill RM, et al. Translocation t(3;8) (p14.2;q24.1) in renal cell carcinoma affects expression of the common fragile site at 3p14 (FRA3B) in lymphocytes. Cancer Genet Cytogenet 1988; 31:69-73.
14. Glover TW, Stein CK. Chromosome breakage and recombination at fragile sites. Am J Hum Genet 1988; 43:265-73.
15. Rassool FV, McKeithan TW, Neilly ME, van Melle E, Espinosa R 3rd, Le Beau MM. Preferential integration of marker DNA into the chromosomal fragile site at 3p14.2: an approach to cloning fragile sites. Proc Natl Acad Sci USA 1991; 88:6657-61. (Pubitemid 21915008)
16. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal cell carcinoma associated translocation breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84:587-97.
17. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, et al. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 1997; 57:504-12.
18. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, et al. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 1997; 57:5207-12. (Pubitemid 27516349)
19. Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, Rugge M, et al. Loss of FHIT expression in gastric carcinoma. Cancer Res 1998; 58:4708-14.
20. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58:5032-7. (Pubitemid 28521154)
21. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, Lee JJ, et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 1997; 89:857-62. (Pubitemid 27268450)
22. Hadaczek P, Siprashvili Z, Markiewski M, Domagala W, Druck T, McCue PA, et al. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res 1998; 58:2946-51. (Pubitemid 28335067)
23. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JT, Kim YT, et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res 1997; 57:4692-8. (Pubitemid 27468968)
24. Simon B, Bartsch D, Barth P, Prasnikar N, Munch K, Blum A, et al. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res 1998; 58:1583-7. (Pubitemid 28215074)
25. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56:3173-9.
26. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, Kononen J, Kallioniemi OP, Barkardottir RB, et al. Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res 1999; 59:2682-9. (Pubitemid 29269116)
27. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999; 59:3866-9.
28. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94:13771-6. (Pubitemid 28009659)
29. Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59:3333-9.
30. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H, et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res. 2001; 61:1578-84. (Pubitemid 34292590)
31. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, et al. Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res. 2001; 61:4827-36. (Pubitemid 32691898)
32. Shiraishi T, Druck T, Mimori K, Flomenberg J, Berk L, Alder H, et al. Sequence conservation at human and mouse orthologous common fragile regions, FRA3B/FHIT and Fra14A2/Fhit. Proc Natl Acad Sci USA 2001; 98:5722-7. (Pubitemid 32435709)
33. Pekarsky Y, Druck T, Cotticelli MG, Ohta M, Shou J, Mendrola J, et al. The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells. Cancer Res 1998; 58:3401-8. (Pubitemid 28371082)
34. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 2000; 97:4742-7. (Pubitemid 30238628)
35. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 2001; 98:10250-5. (Pubitemid 32803006)
36. Ishii H, Dumon KR, Vecchione A, Fong LY, Baffa R, Huebner K, et al. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA 2001; 286:2441-9. (Pubitemid 33098163)
37. Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci USA 2001; 98:3346-51.
38. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, et al. FHIT, a putative tumor suppressor in humans, is a dinucleoside 5′, 5′″-p1, p3 triphosphate hydrolase. Biochemistry 1999; 35:11529-35.
39. Pekarsky Y, Campiglio M, Siprashvili Z, Druck T, Sedkov Y, Tillib S, et al. Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans. Proc Natl Acad of Sci USA 1998; 95:8744-8749. (Pubitemid 28350559)
40. Davidson JN, Peterson M. Origin of genes encoding multi-enzymatic proteins in eukaryotes. Trends Genet 1997; 13:281-5. (Pubitemid 27272078)
41. Chaudhuri AR, Khan IA, Prasad V, Robinson AK, Luduena RF, Barnes LD. The tumor suppressor protein Fhit. A novel interaction with tubulin. J Biol Chem 1999; 274:24378-82.
42. Shi Y, Zou M, Farid NR, Paterson MC. Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9. Biochem J 2000; 352:443-8. (Pubitemid 32011438)